SGI-1027 is primarily utilized in biochemical research as a potent inhibitor of DNA methyltransferases (DNMTs), enzymes responsible for adding methyl groups to DNA, a process known as DNA methylation. This compound is particularly valuable in epigenetic studies, where it helps researchers understand the role of DNA methylation in gene expression and its implications in diseases such as cancer. By inhibiting DNMTs, SGI-1027 can reactivate silenced tumor suppressor genes, making it a promising candidate for cancer therapy research. Additionally, it is used in laboratory settings to investigate the mechanisms of epigenetic regulation and to explore potential therapeutic strategies targeting aberrant DNA methylation patterns in various diseases.